However, potential disadvantages of CD229 targeted therapies could be the development of “on-target off-tissue” toxicity due to its expression in NK cells and T cells and the possibility that sCD229 could hamper CAR T-cell function in patients with MM. Here, LY9 is linked to Miyoshi myopathy.